Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 7/20 | 0.72 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.72 |
| ▸ | P2RX2 | Q9UBL9 | 6/20 | 0.72 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.72 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.72 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.72 |
| ▸ | SRC | P12931 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.69 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.68 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.68 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.68 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.68 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.67 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.66 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | FBP1 | P09467 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1905818 | 1.00 | P2RX3 (0.72) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| SCHEMBL1906288 | 0.99 | P2RY1 (0.74) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| SCHEMBL1906291 | 0.99 | P2RY1 (0.74) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| Thioinosine Monophosphate SCHEMBL29746215 | 0.92 | DNPH1 (0.77) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| Thioinosine Monophosphate SCHEMBL379365 | 0.92 | DNPH1 (0.77) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| Thioinosine Monophosphate SCHEMBL379366 | 0.92 | DNPH1 (0.77) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| Thioinosine Monophosphate SCHEMBL15810629 | 0.92 | DNPH1 (0.77) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| SCHEMBL3862068 | 0.91 | P2RX3 (0.61) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| SCHEMBL3859612 | 0.90 | P2RY1 (0.67) | P2RX3P2RY1P2RX2P2RY2P2RX1 | |
| SCHEMBL3857478 | 0.89 | P2RY1 (0.66) | P2RX3P2RY1P2RX2P2RY2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485171-B2 | Methods of disease activity profiling for personalized therapy management | PROMETHEUS LABORATORIES INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230078652-A1 | METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION | PROMETHEUS LABORATORIES INC (US) | 2023-03-16 | — | — | US | disclosed |
| US-11435347-B2 | Methods for prediction of anti-TNF α drug levels and autoantibody formation | PROMETHEUS LABORATORIES INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20220096629-A1 | METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT | PROMETHEUS LABORATORIES INC. | 2022-03-31 | — | — | US | disclosed |
| US-11219895-B2 | Blood analysis cartridge | KING ABDULAZIZ UNIVERSITY (SA) | 2022-01-11 | — | — | US | disclosed |
| US-11160863-B2 | Methods of disease activity profiling for personalized therapy management | PROMETHEUS LABORATORIES INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210308674-A1 | BLOOD ANALYSIS CARTRIDGE | KING ABDULAZIZ UNIVERSITY (SA) | 2021-10-07 | — | — | US | disclosed |
| US-20210001333-A1 | MICROFLUIDIC DEVICE FOR MEASURING THE ENZYMATIC ACTIVITY OF THIOPURIN S-METHYLTRANSFERASE | KING ABDULAZIZ UNIVERSITY (SA) | 2021-01-07 | — | — | US | disclosed |
| US-10794906-B2 | Assays for detecting neutralizing autoantibodies to biologic therapy | PROMETHEUS BIOSCIENCES, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| US-20200158725-A1 | METHODS FOR PREDICTION OF ANTI-TNF ALPHA DRUG LEVELS AND AUTOANTIBODY FORMATION | PROMETHEUS LABORATORIES INC. | 2020-05-21 | — | — | US | disclosed |
| WO-2013006810-A1 | ASSAYS FOR DETECTING NEUTRALIZING AUTOANTIBODIES TO BIOLOGIC THERAPY WITH TNF ALPHA | NESTEC SA (CH) | 2013-01-10 | — | — | WO | disclosed |
| US-20120329172-A1 | ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES | PROMETHEUS LABORATORIES INC. (US) | 2012-12-27 | — | — | US | disclosed |
| WO-2012154987-A1 | METHODS OF DISEASE ACTIVITY PROFILING FOR PERSONALIZED THERAPY MANAGEMENT | NESTEC SA (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012154253-A1 | ASSAYS FOR DETECTING AUTOANTIBODIES TO ANTI-TNFα DRUGS | PROMETHEUS LABORATORIES INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| EP-2494352-A1 | ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES | Prometheus Laboratories Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| WO-2012054532-A1 | METHODS FOR DETERMINING ANTI-DRUG ANTIBODY ISOTYPES | PROMETHEUS LABORATORIES INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-7972780-B2 | Inosine triphosphate pyrophosphatase (ITPase); predicting tolerance to a thiopurine drug via genotyping; for chronic inflammatory disease and haematological malignancy | GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) | 2011-07-05 | — | — | US | disclosed |
| WO-2011056590-A1 | ASSAYS FOR THE DETECTION OF ANTI-TNF DRUGS AND AUTOANTIBODIES | PROMETHEUS LABORATORIES INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20050202483-A1 | ITPase gene polymorphisms associated with adverse durg reactions to azathioprine therapy | GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) | 2005-09-15 | — | — | US | disclosed |
| WO-2005078125-A2 | ITPASE GENE POLYMORPHISMS ASSOCIATED WITH ADVERSE DRUG REACTIONS TO AZATHIOPRINE THERAPY | GUY'S AND ST. THOMAS' NHS FOUNDATION TRUST (GB) | 2005-08-25 | — | — | WO | disclosed |